These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 26403339)

  • 1. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.
    Goldberger JJ; Bonow RO; Cuffe M; Liu L; Rosenberg Y; Shah PK; Smith SC; Subačius H;
    J Am Coll Cardiol; 2015 Sep; 66(13):1431-41. PubMed ID: 26403339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Landmark Analysis of the Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.
    Goldberger JJ; Subačius H; Marroquin OC; Beau SL; Simonson J;
    J Am Heart Assoc; 2021 Jul; 10(14):e019017. PubMed ID: 34227397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Yang JH; Hahn JY; Song YB; Choi SH; Choi JH; Lee SH; Kim JH; Ahn YK; Jeong MH; Choi DJ; Park JS; Kim YJ; Park HS; Han KR; Rha SW; Gwon HC
    JACC Cardiovasc Interv; 2014 Jun; 7(6):592-601. PubMed ID: 24947717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction.
    Grall S; Biere L; Le Nezet M; Bouvier JM; Lucas-Chauvelon P; Richard C; Abi-Khalil W; Delepine S; Prunier F; Furber A
    Circ J; 2015; 79(3):632-40. PubMed ID: 25746548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of acute beta-blocker therapy on top of aspirin and angiotensin-converting enzyme inhibitor therapy in consecutive patients with ST-elevation acute myocardial infarction.
    Wienbergen H; Zeymer U; Gitt AK; Juenger C; Schiele R; Heer T; Towae F; Senges J;
    Am J Cardiol; 2007 May; 99(9):1208-11. PubMed ID: 17478143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction.
    Rochon PA; Tu JV; Anderson GM; Gurwitz JH; Clark JP; Lau P; Szalai JP; Sykora K; Naylor CD
    Lancet; 2000 Aug; 356(9230):639-44. PubMed ID: 10968437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
    Bangalore S; Bhatt DL; Steg PG; Weber MA; Boden WE; Hamm CW; Montalescot G; Hsu A; Fox KA; Lincoff AM
    Circ Cardiovasc Qual Outcomes; 2014 Nov; 7(6):872-81. PubMed ID: 25271049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
    Park KL; Goldberg RJ; Anderson FA; López-Sendón J; Montalescot G; Brieger D; Eagle KA; Wyman A; Gore JM;
    Am J Med; 2014 Jun; 127(6):503-11. PubMed ID: 24561113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.
    Ozasa N; Morimoto T; Bao B; Furukawa Y; Nakagawa Y; Kadota K; Iwabuchi M; Shizuta S; Shiomi H; Tazaki J; Natsuaki M; Kimura T;
    Int J Cardiol; 2013 Sep; 168(2):774-9. PubMed ID: 23127614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention.
    Ozasa N; Kimura T; Morimoto T; Hou H; Tamura T; Shizuta S; Nakagawa Y; Furukawa Y; Hayashi Y; Nakao K; Matsuzaki M; Nobuyoshi M; Mitsudo K;
    Am J Cardiol; 2010 Nov; 106(9):1225-33. PubMed ID: 21029817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery.
    Zhang H; Yuan X; Zhang H; Chen S; Zhao Y; Hua K; Rao C; Wang W; Sun H; Hu S; Zheng Z
    Circulation; 2015 Jun; 131(25):2194-201. PubMed ID: 25908770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era.
    Nakatani D; Sakata Y; Suna S; Usami M; Matsumoto S; Shimizu M; Hara M; Uematsu M; Fukunami M; Hamasaki T; Sato H; Hori M; Komuro I;
    Am J Cardiol; 2013 Feb; 111(4):457-64. PubMed ID: 23228922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach.
    Zeymer U; Jünger C; Zahn R; Bauer T; Bestehorn K; Senges J; Gitt A
    Curr Med Res Opin; 2011 Aug; 27(8):1563-70. PubMed ID: 21682553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between β-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry.
    Mars K; Wallert J; Held C; Humphries S; Pingel R; Jernberg T; Olsson EMG; Hofmann R
    Eur Heart J Acute Cardiovasc Care; 2021 May; 10(4):372-379. PubMed ID: 33620439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome.
    Lanfear DE; Jones PG; Marsh S; Cresci S; McLeod HL; Spertus JA
    JAMA; 2005 Sep; 294(12):1526-33. PubMed ID: 16189366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of β-Blocker Dose After Acute Myocardial Infarction.
    Hwang D; Lee JM; Kim HK; Choi KH; Rhee TM; Park J; Park TK; Yang JH; Song YB; Choi JH; Hahn JY; Choi SH; Koo BK; Kim YJ; Chae SC; Cho MC; Kim CJ; Gwon HC; Jeong MH; Kim HS;
    Circ J; 2019 Jan; 83(2):410-417. PubMed ID: 30464110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction.
    Dondo TB; Hall M; West RM; Jernberg T; Lindahl B; Bueno H; Danchin N; Deanfield JE; Hemingway H; Fox KAA; Timmis AD; Gale CP
    J Am Coll Cardiol; 2017 Jun; 69(22):2710-2720. PubMed ID: 28571635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-blocker dosage and outcomes after acute coronary syndrome.
    Allen JE; Knight S; McCubrey RO; Bair T; Muhlestein JB; Goldberger JJ; Anderson JL
    Am Heart J; 2017 Feb; 184():26-36. PubMed ID: 27892884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.